Food and Drug Administration

Cardiovascular and Renal Drugs Advisory Committee

June 15, 2005

Briefing Information


The committee will discuss class labeling of antihypertensive drugs 
based on the proximity of their data to outcome trials.


Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. 552)
These redacted portions will appear as white space on the screen or on the printed page.

Proposed Draft Class Labeling